Back to Search
HUNTER CALVERT, DO
DO
Student in an Organized Health Care Education/Training Program
NPI: 1265182885Individual
Specialties, Licenses & Credentials
Student in an Organized Health Care Education/Training ProgramPrimary
Student in an Organized Health Care Education/Training Program
Code: 390200000X
Research & Publications (20)
Phase II studies of polymer-doxorubicin (PK1, FCE28068) in the treatment of breast, lung and colorectal cancer.
PMID 19424581·Int J Oncol·2009
3-trial
Phase I study of MG98, an oligonucleotide antisense inhibitor of human DNA methyltransferase 1, given as a 7-day infusion in patients with advanced solid tumors.
PMID 19383817·Clin Cancer Res·2009
3-trial
A randomised, double-blind, phase II study of two doses of pemetrexed in the treatment of platinum-resistant, epithelial ovarian or primary peritoneal cancer.
PMID 19168349·Eur J Cancer·2009
3-trial
Phase I study of the poly(ADP-ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors.
PMID 19047122·Clin Cancer Res·2008
3-trial
The potential of PARP inhibitors in genetic breast and ovarian cancers.
PMID 18837894·Ann N Y Acad Sci·2008
8-other
Open-label, non-randomised, inter-individual dose escalation of ZK 304709 with the evaluation of safety, tolerability, pharmacokinetics, oral bioavailability and orientating efficacy after daily administration in patients with advanced cancer (7 d treatment and 14 d recovery).
PMID 18653327·Eur J Cancer·2008
3-trial
Mechanisms of chemoresistance to alkylating agents in malignant glioma.
PMID 18483356·Clin Cancer Res·2008
6-review
A novel monoclonal antibody for detection of folate receptor alpha in paraffin-embedded tissues.
PMID 17979543·Hybridoma (Larchmt)·2007
7-preclinical
Population pharmacokinetics and pharmacodynamics of paclitaxel and carboplatin in ovarian cancer patients: a study by the European organization for research and treatment of cancer-pharmacology and molecular mechanisms group and new drug development group.
PMID 17975154·Clin Cancer Res·2007
4-observational
Targeting poly(ADP-ribose) polymerase: a two-armed strategy for cancer therapy.
PMID 17975135·Clin Cancer Res·2007
6-review
Phase 1 and pharmacokinetic study of lexatumumab in patients with advanced cancers.
PMID 17947486·Clin Cancer Res·2007
3-trial
Extracellular heat shock protein 70 has novel functional effects on sea urchin eggs and coelomocytes.
PMID 17371926·J Exp Biol·2007
4-observational
Baseline health-related quality-of-life data as prognostic factors in a phase III multicentre study of women with metastatic breast cancer.
PMID 15093577·Eur J Cancer·2004
3-trial
Novel poly(ADP-ribose) polymerase-1 inhibitor, AG14361, restores sensitivity to temozolomide in mismatch repair-deficient cells.
PMID 14871963·Clin Cancer Res·2004
8-other
Phase I and pharmacokinetic study of E7070, a chloroindolyl-sulfonamide anticancer agent, administered on a weekly schedule to patients with solid tumors.
PMID 14613999·Clin Cancer Res·2003
3-trial
Phase II study of pemetrexed in breast cancer patients pretreated with anthracyclines.
PMID 12881387·Ann Oncol·2003
3-trial
Improvements in quality of life and disease-related symptoms in phase I trials of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in non-small cell lung cancer and other solid tumors.
PMID 12796366·Clin Cancer Res·2003
8-other
Pemetrexed (Alimta): a promising new agent for the treatment of breast cancer.
PMID 12722017·Semin Oncol·2003
6-review
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 1924 ALCOA HWY # U-109
KNOXVILLE, TN 37920 - Phone
- (865) 305-9220
Quick Facts
- NPI
- 1265182885
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile